Biocept Inc. (NASDAQ:BIOC)’s Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Print
By William Kent   
Thursday, 28 May 2015 19:23

Molecular diagnostics company Biocept Inc. (NASDAQ:BIOC), which is involved in developing and commercialising liquid biopsies for improving diagnosis as well as treatment of cancer will carry on building evidence of clinical utility of the liquid biopsy offerings and give an abstract at 2015 Annual American Society of Clinical Oncology Meeting in Chicago.

The firm provides quantitative blood-based method for detecting as well as monitoring of clinically actionable cancer biomarkers for helping doctors make treatment decisions depending on genomic information.

 

The firm is involved in a number of clinical studies made for showing use of liquid biopsy diagnostic for detecting patient’s biomarker status as well as assessing treatment response over time.

 

The abstract shows that the

clinical utility is not just for a patient having insufficient tissue from a biopsy but even for better representation through avoiding of challenges linked to tissue heterogeneity.

. Lyudmila Bazhenova, MD, Associate Clinical Professor of Medicine at University of California, San Diego Moores Cancer Center, opined that by giving oncologists with genomic testing results, the firm is able to stratify patients depending on biomarker status in real-time. He added that this has the

Error. Page cannot be displayed. Please contact your service provider for more details. (18)

potential of transforming how patients with solid cancers like non-small cell lung cancers are monitored.

Veena Singh, MD, Sr. VP and Medical Director at Biocept, opined that the comfort of real-time monitoring as well as early identification of emergence of resistance lowers time to make treatment change that is crucial for metastatic cancer.

She added that the health economic benefit of getting actionable biomarker status is an added advantage to the

health care system.

Even though the next-generation of therapies will be out in the market, it would be essential that clinicians have a method for serial monitoring for understanding when they are candidates for these therapies. 




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1